Jul 30, 2025

Dr. John Granton, a critical care and transplant physician at Toronto General Hospital, shares his journey in pulmonary hypertension and lung transplantation, detailing the groundbreaking advancements in transplant technology. He discusses the evolution of lung preservation methods, the challenges of chronic rejection, and the hope for longer-lasting transplants. With a passion for improving patient outcomes, Dr. Granton envisions a future where transplant becomes obsolete—replaced by treatments that cure underlying diseases.
My
name is John Granton. I'm in Toronto. That's where I was born, just
north of the city. I trained mainly in Canada, trained in London,
Ontario and then went to McMaster and then University of Toronto
and then University of British Columbia for a while and came back.
I've been on staff there for about 30 years now at the Toronto
General Hospital, primarily. I work as a critical care doc looking
after sick patients who come in ill or after major surgery like
transplant. I've also worked in the transplant space for many years
as a transplant physician, but more commonly now as a critical care
doc, looking after people after transplant.
We started a pulmonary hypertension program in 1997. At the time,
the head of transplant, Stephen Kestin, looked to me and I'd just
come on staff. The paper on Flolan had just come out and he said,
"We need somebody to do this." He said, "You like hemodynamics and
stuff and you're a critical care doc. Why don't you do this?" I
said, "Okay." I got some money together. We hired a nurse
part-time, put a sign on the lawn and we've grown. We're a big
program. Because of the resource, we serve a lot of different
communities. We offer the range of critical care and transplant
services in addition to pulmonary hypertension services as a major
referral center. We also provide medical treatments, diagnostics,
chronic thromboembolic pulmonary hypertension management, so major
surgery.
I’m really here today to talk about the transplant aspect. Our
program in Toronto is a big program. We transplant over 200
patients each year, so it makes us pretty much the largest program
worldwide and a highly innovative program ,as well, doing a lot of
really cool things, which ultimately will benefit patients by
providing them with access to more lungs, so they have the
opportunity to benefit from transplant, and also looking towards
better outcomes for transplant.
One of the major things we're doing is looking at the role of when
we get a lung from somebody who's died or a set of lungs from
somebody who's died, we put them on this machine, which actually
profuses it. We run a solution through it and we support it, kind
of in an animated state, which allows us to check out the lung to
make sure the lung's okay, functioning well, make sure there's no
pneumonia. We can look into the lung with a small scope. We can
take x-rays, CT scans. Our group's now modifying the lung, so you
can actually treat the lung to make it better. You can make it
perhaps more acceptable for the person, so they don't have to use
as much immunosuppressants to suppress their immune system so they
don't get infections and stuff, so they can tolerate the new lungs
with their immune system better. Ultimately that will lead to
better outcomes.
The major problem with transplant right now is that once you're
committed to transplant, those lungs are yours. We know that in
addition to the trouble with the drugs, those lungs will eventually
fail because the body will continue to try to reject them. That's
been the major limitation to transplant. Hopefully, with this kind
of technology and availability and understanding of the biology and
how things work, we're going to be able to manipulate those lungs
so that they've got a much longer shelf life, if you will, and
carry the patients through for a lot longer than it currently is.
Usually, when we identify somebody, a set of lungs for a person, we
call the person and we also call another person often as a backup,
just in case something's going on. You can only have the lungs
outside of a person's body for a period of time before it starts to
deteriorate.
Having it on the system actually allows them to be animated for a
longer period of time, so you can kind of coordinate things a
little bit. Previously ,people had to live close to the hospital.
They couldn't be more than a couple of hours drive, because they
had to be available to go to the operating room real quick and you
had to make decisions fairly quickly. Now, it puts us in the
position where we can bring people in, they can drive from home a
few hours away. When they're in the hospital, they kind of go in a
waiting room and they sit there and hope that the lungs are going
to be okay. Often, it's a dry run because the lungs don't turn out
okay, because there's something wrong with them or they
deteriorate. When you start to look at them, they're not performing
well, so you don't want to put it in the person.
Even though that's discouraging for the person, it otherwise avoids
them getting a set of lungs which may not have served them well. I
think it also increases confidence that the lungs you're putting in
are probably going to be good and you've improved them and they're
looking better, and so you're much more confident in transplanting
them into the person who's waiting. In the old days, you didn't
have that confidence and so you turned away a lot of lungs that
might've otherwise been pretty good, but also you may have put in
some lungs which you wish you hadn't because things start to turn
sour fairly quickly. Once they're in somebody, you can't look
back.
Transplant used to be kind of an experimental therapy. Now, it's an
established therapy. Treatments have improved and medications,
particularly cyclosporine allowed transplant to occur successfully.
Previously most grafts, kidneys, livers, lungs would fail very
quickly. The advent of cyclosporine really allowed transplant to
occur.
The problem with lungs is of all the organs, they tend to do the
worst long-term. The reason for that is this ongoing rejection that
can damage the lungs and cause them to not work properly and
patients often have to go back on oxygen and other things like that
and they start to feel short of breath and their quality of life,
frankly, starts to deteriorate. If you look at things like
survival, the average survival in many programs is about seven,
maybe eight years for pulmonary hypertension. If you get through
the initial phase, pulmonary hypertension patients who are
transplanted do better than other reasons for being transplanted
like COPD or interstitial lung disease, IPF. They still succumb
eventually from this problem and we're trying to manipulate that,
but we haven't found the secret recipe yet to prevent that from
happening.
We're hoping that by conditioning the lungs early on, allowing
better tolerance of the lungs will prevent that lungs standing kind
of erosion of the lungs because of ongoing rejection or attempts at
the body to try to get rid of those lungs, which can damage them.
We haven't found that yet, and it really is the Achilles heel of
lung transplantation, this chronic rejection. We do occasionally
have to retransplant somebody. We never really go in saying, if
these lungs don't work out, you're going to get retransplanted,
because we don't know if that person would be eligible for another
of lungs.
Generally, you go into transplant with the understanding that's
probably your shot at it, with those sets of lungs. Occasionally,
we can re-transplant people, but that's usually the exception as
opposed to the rule. After transplant, because of the medications,
you accumulate a lot of complications and you're also a bit older
and you're also subject to the same kind of conditions that
everybody else gets. Heart disease, kidney disease, liver disease,
other things. Whereas you might've been a good transplant candidate
at the time you got your first set of lungs, you may not be a good
transplant candidate by the time you need a second set of lungs.
So, you really have to hope that those lungs carry you through.
Even though we talk about the average survival being seven and a
half, seven, eight years after transplant, but some people don't do
well early on, but many patients do better than that. I still have
some of my patients, I still run into the hallways 20 years after
transplant. That's amazing. It's still too short. If you're a young
person, 10 years is still a short period of time, so we'd like to
be able to offer everybody a normal lifespan and look forward to
that one day.
Secretly, I hope transplant goes out of business. That'd be
fantastic, so that you could actually treat the underlying
conditions and people would never need a transplant again. That is
the ultimate. Transplant is really a failure of medical therapies
to treat the underlying condition, whether it be heart disease,
kidney disease, liver disease, whatever. Some of it is
self-inflicted. We do recognize addictions that can cause lung
disease and liver disease. Not so true for pulmonary arterial
hypertension or people have pulmonary hypertension from other
causes. Apart from those instances, but also treat people who have
those addictions better, but also treat people with pulmonary
arterial hypertension in particular with novel medications which
might reverse the disease and at the very least prevent further
progression of the disease so that people won't need transplant.
That's kind of the holy grail is to get to that point. I don't
think any of us would lose sleep if we never had to send our
patients for transplant.
When you actually start talking about time though, when your life
expectancy with the condition you have is worse than the life
expectancy after transplant, and that's kind of the trade-off. You
have to decide, okay, if average survival after transplant is seven
and a half years, what's my average survival right now? If it's
less than seven and a half years, then that's probably you're going
to want to start thinking about transplant. Some conditions and the
level of severity means that you're much higher risk of not
surviving the next year or two. So, transplant becomes much more in
the moment the conversation. It's a tough conversation because it's
hard talking about the future and what that looks like and
accepting your mortality and the timing of that. It's an upsetting
conversation to have with people and it's upsetting for them and
traumatic for them and their family to have those conversations.
They thought about it.
There's another conversation though that I often find is a bit
easier is that, “What's your quality of life like right now?” If we
can't make that better through medication, we tried everything, at
what point does your quality of life get so impaired and you're so
unhappy with the way you're living and the things you can't do that
you would be willing to risk your current situation for something
better like transplant. I think having that quality of life
conversation is a little easier sometimes than having the death
conversation, because ultimately we accept that we're all going to
die one day, but we hope we live well up until that point. That's
the way I frame the conversation. It's much more around, “Let's
talk about ways to improve your quality of life.” Transplant is a
way of doing that.
It's hard to generalize, but I get a kick out of seeing patients
after a successful transplant. I don't even recognize some of my
patients ,because you saw them when they couldn't walk and they
were carrying oxygen. I remember people with cystic fibrosis, they
couldn't get along and they were coughing, a terrible quality of
life. People with pulmonary hypertension really having to stop and
pause and do things when you catch them walking from the waiting
room or down the hall or wherever. Then, they're walking briskly to
have their lung function done. Or I seem them out in the street
somewhere and you just don't recognize them. They tap me on the
shoulders. It's fantastic. As I said, some of the patients I've
known for 10, now 20 years, you run into them and it's amazing. I
get a real kick out of that.
To me, it's been transformative. Even those patients who I see who
aren't doing well and maybe they're starting to get some rejection
or their lung function's deteriorating, I ask them, “Was it worth
it? Would you do it again?” They say, “Yeah, I would do it again.
The years that I had were amazing. I was able to do things I could
never do. I really got to enjoy my family. I traveled, I started
riding, walking, hiking,” whatever they enjoy doing. That's really
what it's all about, to get them back to that point where they want
to be and live life. It's fun when they're able to do that.
My name is John Granton and I'm aware that my patients are
rare.
Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @UHN @teamphhope #phawareMD #PHILD #transplant @phacanada